Do analysts recommend ERGO or PRTC?

PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 279.10%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, ERGO or PRTC?

Ergomed has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ergomed £152.09M 0.00 £15M £0.29 N/A PureTech Health £4.66M 70.01 -£91.86M -£46.00 N/A

Is ERGO or PRTC more profitable?

Ergomed has a net margin of 9.87% compared to PureTech Health's net margin of -2,355.32%. Ergomed's return on equity of 18.08% beat PureTech Health's return on equity. Company Net Margins Return on Equity Return on Assets Ergomed 9.87% 18.08% 10.16% PureTech Health -2,355.32% -31.98% -13.39%

Do analysts rate PRTC or SLN?

PureTech Health currently has a consensus price target of GBX 508, indicating a potential upside of 279.10%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe PureTech Health is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

PureTech Health (PRTC) Competitors

GBX 134 +2.80 (+2.13%)

As of 06/29/2026 11:56 AM Eastern

Compare

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Oxford Nanopore Technologies has a beta of 0.914, indicating that its stock price is 9% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.811, indicating that its stock price is 19% less volatile than the broader market.

19.6% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 34.0% of PureTech Health shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Comparatively, 13.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oxford Nanopore Technologies has a net margin of -64.85% compared to PureTech Health's net margin of -2,355.32%. Oxford Nanopore Technologies' return on equity of -29.43% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Oxford Nanopore Technologies currently has a consensus target price of GBX 218.60, suggesting a potential upside of 75.76%. PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 279.10%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

PureTech Health has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	5.40	-£175.21M	-£15.10	N/A
PureTech Health	£4.66M	70.01	-£91.86M	-£46.00	N/A

In the previous week, PureTech Health had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Oxford Nanopore Technologies. PureTech Health's average media sentiment score of 0.67 beat Oxford Nanopore Technologies' score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Neutral
PureTech Health	Positive

Summary

PureTech Health beats Oxford Nanopore Technologies on 10 of the 16 factors compared between the two stocks.

How does PureTech Health compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
PureTech Health	-2,355.32%	-31.98%	-13.39%

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 34.0% of PureTech Health shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Comparatively, 13.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oxford Biomedica has a beta of 1.096, meaning that its stock price is 10% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.811, meaning that its stock price is 19% less volatile than the broader market.

PureTech Health has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.50	-£143.51M	-£26.92	N/A
PureTech Health	£4.66M	70.01	-£91.86M	-£46.00	N/A

In the previous week, Oxford Biomedica and Oxford Biomedica both had 1 articles in the media. PureTech Health's average media sentiment score of 0.67 beat Oxford Biomedica's score of -0.50 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Negative
PureTech Health	Positive

Oxford Biomedica currently has a consensus price target of GBX 600.04, indicating a potential downside of 4.45%. PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 279.10%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

PureTech Health beats Oxford Biomedica on 8 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Ergomed?

Ergomed (LON:ERGO) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Ergomed has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
PureTech Health	£4.66M	70.01	-£91.86M	-£46.00	N/A

Ergomed has a net margin of 9.87% compared to PureTech Health's net margin of -2,355.32%. Ergomed's return on equity of 18.08% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.811, indicating that its share price is 19% less volatile than the broader market.

In the previous week, PureTech Health had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Ergomed. PureTech Health's average media sentiment score of 0.67 beat Ergomed's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Ergomed	Neutral
PureTech Health	Positive

PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 279.10%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 34.0% of PureTech Health shares are owned by institutional investors. 18.2% of Ergomed shares are owned by insiders. Comparatively, 13.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ergomed beats PureTech Health on 9 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Silence Therapeutics?

PureTech Health (LON:PRTC) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Silence Therapeutics has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	70.01	-£91.86M	-£46.00	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

PureTech Health currently has a consensus price target of GBX 508, indicating a potential upside of 279.10%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe PureTech Health is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

34.0% of PureTech Health shares are held by institutional investors. 13.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silence Therapeutics has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Silence Therapeutics' return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Silence Therapeutics	N/A	N/A	N/A

In the previous week, PureTech Health had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Silence Therapeutics. PureTech Health's average media sentiment score of 0.67 beat Silence Therapeutics' score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Positive
Silence Therapeutics	Neutral

Summary

PureTech Health beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Avacta Group?

Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -33,961.06%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
PureTech Health	-2,355.32%	-31.98%	-13.39%

In the previous week, PureTech Health had 1 more articles in the media than Avacta Group. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Avacta Group. PureTech Health's average media sentiment score of 0.67 beat Avacta Group's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Avacta Group	Neutral
PureTech Health	Positive

Avacta Group presently has a consensus target price of GBX 99, indicating a potential upside of 30.26%. PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 279.10%. Given PureTech Health's higher probable upside, analysts plainly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.811, indicating that its stock price is 19% less volatile than the broader market.

Avacta Group has higher earnings, but lower revenue than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,060.92	-£30.08M	-£9.66	N/A
PureTech Health	£4.66M	70.01	-£91.86M	-£46.00	N/A

2.9% of Avacta Group shares are owned by institutional investors. Comparatively, 34.0% of PureTech Health shares are owned by institutional investors. 49.1% of Avacta Group shares are owned by insiders. Comparatively, 13.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

PureTech Health beats Avacta Group on 9 of the 14 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£326.18M	£508.43M	£6.85B	£2.78B
Dividend Yield	N/A	3.87%	2.66%	6.14%
P/E Ratio	-2.91	3.11	26.04	366.54
Price / Sales	70.01	6,785.72	550.14	85,951.69
Price / Cash	2.14	13.13	29.09	27.87
Price / Book	1.18	89.37	10.98	7.75
Net Income	-£91.86M	-£96.07M	£3.57B	£5.89B
7 Day Performance	1.52%	0.51%	2.60%	-0.10%
1 Month Performance	-3.46%	-0.48%	0.93%	-1.69%
1 Year Performance	7.54%	72.30%	36.40%	65.41%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	1.8982 of 5 stars	GBX 134 +2.1%	GBX 508 +279.1%	+6.0%	£326.18M	£4.66M	N/A	300
ONT Oxford Nanopore Technologies	N/A	GBX 122.02 +0.6%	GBX 218.60 +79.2%	-8.4%	£1.19B	£223.90M	N/A	1,281	Positive News High Trading Volume
OXB Oxford Biomedica	0.7871 of 5 stars	GBX 628 -0.9%	GBX 600.04 -4.5%	+98.7%	£759.94M	£168.74M	N/A	891	Gap Down High Trading Volume
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRTC) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

How does PureTech Health compare to Oxford Nanopore Technologies?

Summary

How does PureTech Health compare to Oxford Biomedica?

Summary

How does PureTech Health compare to Ergomed?

Summary

How does PureTech Health compare to Silence Therapeutics?

Summary

How does PureTech Health compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

How does PureTech Health compare to Oxford Nanopore Technologies?

Which has more volatility and risk, ONT or PRTC?

Do insiders and institutionals have more ownership in ONT or PRTC?

Is ONT or PRTC more profitable?

Do analysts recommend ONT or PRTC?

Which has better earnings and valuation, ONT or PRTC?

Does the media favor ONT or PRTC?

Summary

How does PureTech Health compare to Oxford Biomedica?

Is OXB or PRTC more profitable?

Do insiders and institutionals believe in OXB or PRTC?

Which has more volatility & risk, OXB or PRTC?

Which has preferable valuation and earnings, OXB or PRTC?

Does the media refer more to OXB or PRTC?

Do analysts rate OXB or PRTC?

Summary

How does PureTech Health compare to Ergomed?

Which has preferable earnings and valuation, ERGO or PRTC?

Is ERGO or PRTC more profitable?

Which has more volatility & risk, ERGO or PRTC?

Does the media favor ERGO or PRTC?

Do analysts recommend ERGO or PRTC?

Do insiders & institutionals believe in ERGO or PRTC?

Summary

How does PureTech Health compare to Silence Therapeutics?

Which has better valuation & earnings, PRTC or SLN?

Do analysts rate PRTC or SLN?

Do institutionals and insiders believe in PRTC or SLN?

Is PRTC or SLN more profitable?

Does the media favor PRTC or SLN?

Summary

How does PureTech Health compare to Avacta Group?

Is AVCT or PRTC more profitable?

Does the media refer more to AVCT or PRTC?

Do analysts prefer AVCT or PRTC?

Which has more risk & volatility, AVCT or PRTC?

Which has better earnings & valuation, AVCT or PRTC?

Do institutionals & insiders believe in AVCT or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools